Bevacizumab synergises with the BCL 2 inhibitor venetoclax to effectively treat B‐cell non‐Hodgkin's lymphoma-Reference-Cited by-同舟云学术

Bevacizumab synergises with the BCL 2 inhibitor venetoclax to effectively treat B‐cell non‐Hodgkin's lymphoma

Published:2019-07-03 Issue:3 Volume:103 Page:234-246
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Wang Li¹,Peng Shaoyong²,Sun Weipeng²,Liu Xiaoxia¹²³^ORCID

Affiliation:

1. Department of Pharmacy, Zhujiang Hospital Southern Medical University Guangzhou China

2. The Sixth Affiliated Hospital, Guangdong Institute of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Supported by National Key Clinical Discipline Sun Yat‐sen University Guangzhou China

3. Sun Yat‐Sen University Cancer Center, State Key Laboratory of Oncology in Southern China Collaborative Innovation Center for Cancer Medicine Guangzhou China

Funder

National Natural Science Foundation of China

China Postdoctoral Science Foundation

Natural Science Foundation of Guangdong Province

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13279

Reference44 articles.

1. Epidemiology of non-Hodgkin?s lymphoma (NHL): trends, geographic distribution, and etiology